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1. Introduction
Neutrophil cells: were discovered by Elie Metchnikoff as an inflammatory immune response
to rose thorns inserted in starfish larvae [1].
Neutrophils are a major type of white blood cell (WBC), and they represent about 45%-70% of
all WBC. Neutrophils can also be referred to as poly-morphonucleat leucocytes or granulo‐
cytes, as their cytoplasm contains granules, which contains glycogen and antibacterial
substances [2]. Neutrophils are synthesized and produced by hematopoietic stem cells in bone
marrow. It takes 10 – 14 days to produce mature neutrophils. Neutrophils were first thought
to have a short viability period of only 6-10 hours [2, 3], but in the late 1990s, it was that
neutrophils may survive much longer. In addition, recent evidence has suggested that
neutrophils may produce anti-inflammatory molecules and may promote the resolution of
inflammation [4]. Moreover, it has been found that during inflammation or infection, neutro‐
phils will migrate to the inflamed tissues, phagocytosis and remain active at site for about 2-6
days [2, 4, 5].
2. Synthesis and production of neutrophils cells
Neutrophil production and synthesis is a major activity of the bone marrow. In fact, two-thirds
of blood cell synthesis in bone marrow is dedicated to the production of monocytes and
granulocytes. Hematopoietic stem cells are characterized by little blood flow and low oxygen
tension, while the more mature and actively dividing stem cells reside closer to the abluminal
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side of the sinusoids, the special vascular structure of the bone marrow. The chemokine
receptor CXCR4 is essential for the homing of stem cells and more mature neutrophils to the
bone marrow [6].
Deletion of CXCR4 causes mature neutrophils to be released from the bone marrow into
circulation without affecting the life-span of circulating neutrophils [6, 7].
The production of neutrophils is extensive, with 1 - 2 × 1011 cells being generated per day in a
normal adult human. Granulocyte colony stimulating factor (G-CSF) is essential for tuning the
production of neutrophils to meet the increased needs that occur during infections, but G-CSF
is not absolutely required for granulocytopoiesis. Indeed, G-CSF null mice have approximately
25% residual granulocytopoiesis and still generate fully mature neutrophils [6]. The produc‐
tion of neutrophils is largely regulated by the rate of apoptosis of neutrophils in tissues. When
macrophages and dendritic cells phagocytose apoptotic neutrophils in tissues, the production
of interleukin 23 (IL-23) is reduced [6].
3. The role of neutrophils
Neutrophils are the body’s first line of innate defense from micro-organismsand and inflam‐
mation. Neutrophils are able to bind to and ingest invading microorganisms such as bacteria,
fungi, germs, or any foreign body in the blood by a process known as phagocytosis, most likely
due to their defensive and/or phagocytic process is by their ability to release lytic enzymes
from their granules and to produce reactive oxygen intermediates (ROI) [2, 3, 4, 8].
Neutrophils cells directly recognize surface-bound or freely secreted molecules produced by
bacteria (i.e., pathogen-derived molecules), including peptidoglycan, lipoproteins, lipoteicho‐
ic acid, lipopolysaccharide (LPS), CpG-containing DNA, and flagellin. These pathogen-
derived molecules, known as pathogen-associated molecular patterns, interact directly with a
number of pattern-recognition receptors expressed on the cell surface of neutrophil cell.
Pattern-recognition receptors play a role in the recognition of microbes by neutrophils, and
the efficiency of phagocytosis by neutrophils is markedly enhanced if microbes are opsonized
with serum host proteins, such as complement and/or antibody [9].
Neutrophils have receptors on their surface that help them to contact and bind to tissues and
to the vascular endothelium near sites of infection or inflammation [2] and they are the first
cells that migrate to the site of invasion or inflammation to start the clearance of infectious
particles. In the events of invading foreign threat, they also send warning signals to other innate
immune cells [1].
Thus the migration of neutrophils from the blood circulation to surroundings tissues is
considered key in triggering host defense.
During the process of migration to site of invasive, neutrophils need to cross the vessel wall
(transmigration). This takes place largely at postcapillary venules, where the vessel wall is
rather thin, and the diameter of the vessel is sufficiently small that the neutrophils can make
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contact with the vessel wall, and is yet not occluded by neutrophils when they arrest and make
firm contact with the endothelium [6, 9, 10]. Neutrophil transmigration is a highly regulated
process that requires the up-regulation of neutrophils and endothelial cell adhesion molecules.
During neutrophil adhesion to endothelial cell, binding of neutrophils or endothelial cell
adhesion molecules to their ligands may induce intracellular signaling pathways and down‐
stream events, which may in turn modulate neutrophil transmigration. Indeed, the ligation of
various adhesion molecules can initiate signal transduction pathways and induce subsequent
cellular changes [11, 12].
Moreover, it has been found that neutrophils that migrate through tissues are more effective
phagocytic cells than blood neutrophils that is non-migrating neutrophils [6]. Therefore,
neutrophils have emerged as key components of the effector and regulatory circuits of the
innate and adaptive immune systems, and this has led to a renewed interest in their biology
[4]. Recent studies have shown that human neutrophils are a major source of cytokines, which
are crucial for the survival, maturation, and differentiation of B cells, and are also involved in
bone resorption [4].
4. Process of neutrophil cells penetration to the tissues
Migration of neutrophil cells from blood circulation into the surrounding tissues, this process
consider as the key role that trigger host defense. Neutrophil transmigration across the
vascular endothelium is a highly regulated process that requires the up-regulation of neutro‐
phil and endothelial cell (EC) adhesion molecules. During neutrophil adhesion to ECs, binding
of the neutrophil or EC adhesion molecules to their ligands may induce intracellular signaling
pathways and downstream events, which may in turn modulate neutrophil transmigration.
Indeed, the ligation of various adhesion molecules can initiate signal transduction pathways
and induce subsequent cellular changes [11].
5. Neutropenia
Neutropenia is defined as a decrease in the absolute number of neutrophils in the blood.
Clinically, neutropenia is defined as a decrease in the absolute neutrophil count (ANC) of more
than two standard deviations below the normal range. Therefore, the patient is considered
neutropenic when the ANC is lower than 1500 cells/μl (the normal level) [2, 3, 5, 13, 14]. An
ANC above 1000 cells/μl will still confer normal protection against infection; therefore mild
neutropenia is defined as an ANC 500 - 1000 cells/μl. There is a significant increase in the
incidence of serious infection once ANC falls below 500 cells/μl, and moderate neutropenia is
defined as an ANC of 200 - 500 cells/μl [2, 3, 13]. When ANC falls below 200 cells/μl it is defined
as severe neutropenia. This condition is very serious and requires the patient to be admitted
to the hospital and treated with antibiotics [3, 13], and patients with an ANC below 100 cells/
μl are at the highest risk of infection. Hundred percent of the patients with ANC < 100 cells/μl
lasting 3 weeks or more develop documented infection.
A Close Look at Neutropenia among Cancer Patients — Risk Factor and Management 3
Neutropenia is usually diagnosed by a complete blood count (CBC) or full blood count (FBC).
If the results show a low ANC then these tests are repeated [15]. If the repeated test shows the
same results, a bone marrow biopsy is carried out to confirm the diagnosis. Bone marrow
aspirate is taken from two sites, one from the middle of the bone and one from the solid, bonier
part of the bone, usually from the large pelvic bone, the ilium, or the sternum [15].
Febrile neutropenia (i.e., neutropenia with fever) is mostly associated with chemotherapy, but
it may also occur after irradiation of the bone marrow. In this chapter, the term febrile
neutropenia is usually used to describe the occurrence of neutropenia (body temperature
≥38.3°C or oral temperature ≥38°C for more than hour) and an ANC of ≤ 500 cells/μl at the time
of fever, or in the following 48 hours [2, 14, 15, 16, 17, 18].
6. Adverse effects
Neutropenia has many negative effects. One of these side effects is dose reduction of chemo‐
therapy. Fifty percent (50%) of cancer patients received less than 85% of the prescribed doses
because of neutropenia.
Neutropenia can also cause delays in chemotherapy treatment, which can lead to increase in
cancer cell growth and tumor size. Both dose reduction and delay of chemotherapy can have
serious effects on patients’ lives, and may even lead to death [19, 20].
Neutropenia also has a dramatic and detrimental effect on the patients’ quality of life. Fatigue
is the predominant characteristic, which leads to a decrease in the ability to perform daily life
activities. Patients describe fatigue as feeling weak and exhausted. Psychological problems
were also reported by the patients, such as sadness, anxiety, reduced self-worth, and inability
to fulfill normal roles [19, 20].
7. Neutropenia diagnosis
The diagnosis of neutropenia is usually made by performing the following tests:
7.1. Complete blood count
The first test to investigate the suspicion of neutropenia presence is to perform complete blood
count (CBC) or full blood count (FBC) whereby the neutrophil numbers will be measured. If
the results showed a low neutrophil count then these tests will be repeated in order to be certain
that neutropenia is actually present [21].
7.2. Bone marrow aspirate/trephine biopsy
After performing a blood test, a bone examination could be carried out to confirm the results.
Bone marrow biopsy is done by obtaining bone marrow aspirates from two sites that are from
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the middle of the bone and also from solid bonier part of the bone. This bone biopsy is
performed with the patient under general anesthesia or local anesthesia with sedation. These
bone marrow samples are usually taken from the large bones such as large pelvic bone, the
ilium, or sometimes from the flat breastbone (i.e., the sternum) [21].
8. Causes of neutropenia
Demographic factors, hematological disorders, autoimmune diseases, infections, drugs
reactions, and chemotherapy or radiotherapy play a major role in the etiology of neutropenia
[2, 13, 17]. Neutrophil production is lower among older people; they are not as able to produce
mature neutrophil as younger people, and ANC in White men is higher than that in Black men.
Also neutropenia incidence seems to be higher in women than men [2, 13, 14]. Hematological
diseases like leukemia, myelodysplastic syndrome, Hodgkin’s and non-Hodgkin’s diseases,
and multiple myeloma have also been shown to cause neutropenia [2]. In these hematological
diseases, severe destruction of bone marrow leads to the destruction of stem cells. This will
result in the prevention of or decrease in neutrophil production, thus causing neutropenia [2].
Moreover, these hematological diseases can have an effect on the red blood cells (RBC) and
platelet production which can lead to severe anemia and thrombocytopenia. Usually the
patient will suffer from fever ≥ 38.5°C as well as gingivitis, bleeding, stomatitis, bone chills,
and the patient might also collapse [22]. Neutropenia has also been associated with autoim‐
mune diseases like systemic lupus erythromatosis (SLE). Neutropenia following SLE is usually
mild and the patient may not suffer from serious bacterial infection. However patients with
Sjören syndrome and rheumatoid arthritis may have severe neutropenia, leaving them at
higher risk of bacterial or fungal infection [2]. Many drugs such as diuretics, chlorpromazine,
and allopurinol have been shown to cause neutropenia, and two mechanisms for this have
been suggested. The first postulates that the drug produces dose-dependent toxicity on cell
production, protein synthesis, bone marrow, and cell survival. The second suggests a mecha‐
nism of drug-inducing immunological reactions, for example, the binding of drugs with the
surface of the neutrophil cell, leading to cell destruction and neutropenia. These two mecha‐
nisms are not always seen; they happen in only a small percentage of patients. These two
mechanisms also require a long duration of drug use [2].
9. Chemotherapy
Neutropenia is mostly associated with chemotherapy and radiotherapy. Chemotherapeutic
drugs affect the production of folic acid as well as the synthesis of DNA, RNA and protein by
acting as anti-metabolites, which lead to bone marrow destruction [2, 13, 14, 22]. Bone marrow
destruction in turn leads to a decrease in neutrophil production. Therefore, chemotherapy and
radiotherapy are considered to be the main causes of neutropenia and febrile neutropenia.
Besides that, chemotherapeutic drugs kill and suppress all the cells that have a high rate of
division or affect blood cells, bone cells, and neutrophil cells (Fortner et al., 2005). The chemo‐
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therapeutic drugs actinomycin, asparaginase, cytarabine, busulfan, cisplatin, daunorubicin,
etoposide, fluorouracil, ifosfamide, and methotrexate are highly associated with neutropenia
development [2, 14, 23].
The link between chemotherapy and neutropenia was emphasized by Buffoni et al. (2006) who
looked at the effect and toxicity of chemotherapeutic drugs on 30 non-small lung cancer
patients treated with a combination of cisplatin and vinorelbine on day 1 and day 8 and
repeated every 21 days. The major toxic effect associated with these chemotherapies was
neutropenia 3 and 4 (63%). The treatment also caused three deaths, two of which were due to
febrile neutropenia. Hence it can be concluded that even though the combination of cisplatin
and vinorelbine was very effective in the treatment of lung cancer, it was also associated with
neutropenia, some of which was fatal [24].
Yamanaka et al. (2007) conducted a study 1055 patients in Japan with advanced gastric cancer
on oral fluoropyrimidine derivatives (S-1). The main important result of the study was that
neutropenia incidence was an inadequate predictor of increased survival in these patients.
Also the another important point of their study was that the absence of neutropenia indicated
that the doses of the chemotherapeutics drugs were not intensive enough to cause neutropenia
[25]. This point was also indicated in the observational retrospective study carried out in
Penang Hospital on 117 solid tumor patients who were admitted between January 2003 and
December 2006, and treated with various types of chemotherapy regimens. The highest
chemotherapeutic regimen received in this study was (5-FU + epirubicin + cyclophosphamide)
(47, 40.2%), followed by (gemcitabine + cisplatin) (6, 5.1%), and others. The majority of the
patients in the study were on a 1-day chemotherapy administration schedule of (90, 76.9%),
followed a schedule of more than one day (27, 23.1%). The statistical analysis of Chi-square
test results showed insignificant associations between chemotherapy type and neutropenia
incidence (P=0.798) and neutropenia severity (P=0.199). The same results were found between
neutropenia incidence and chemotherapy administration schedule and duration (P=0.689) and
neutropenia severity (P=0.434).
The main explanation for these results was that the doses of these drugs were not high
enough  to  cause  bone  marrow  suppression  and  lead  to  neutropenia.  Moreover,  the
administration schedule for each drug was long enough to overcome neutropenia, and the
high use of G-CSF likely played a major role in reducing the time and neutropenia severity.
All  these  factors  likely  contributed  to  the  non-significant  association  observed  between
neutropenia  incidence  and  severity,  and  chemotherapeutics  drugs  and  administration
schedule [26]. The correct doses of chemotherapeutic drugs must be used in order to prevent
the incidence of lethal neutropenia [27].
Another study looking at the association between neutropenia and chemotherapy drugs was
conducted by Banerji et al. (2006) in the United Kingdom. The study involved 173 patients
treated with etoposide and carboplatin. The results obtained from the study showed a
significant association between neutropenia and the chemotherapy drugs (P <0.0001) [28].
However, different chemotherapy regimens are not associated with the same neutropenia
severity. This difference is due to substantial variations in the resiliency of hematopoietic
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tissues among cancer patients and chemotherapy tolerance. Moreover, severe neutropenia has
been reported in patients with solid cancers, especially breast cancer patients, when treated
with cyclophosphamide, methotrexate and 5-fluorouracil (CMF), suggesting that neutropenia
is associated with the intensity of the chemotherapy regimens [8], for example, the doses of
cytotoxic drugs such as epirubicin, cisplatin, doxorubicin, vincristine, capecitabine, carbopla‐
tin, and bleomycin were not high or intensive and they do not seem to cause severe neutropenia
(i.e., neutropenia is considered a minor side-effect for these chemotherapies). But these low
chemotherapy doses can cause other major adverse effects like nausea, vomiting, thrombocy‐
topenia, alopecia, and anemia [29, 30, 31].
9.1. Role of route of chemotherapy administration
The route of chemotherapy administration could be either systematic which includes: intra‐
venous (I.V), oral, and intramuscular (I.M) or local intrathecal, intraperitoneal, intra-arterial,
and intrapleural. The most commonly used administration routes are the intravenous and the
oral route. The advantage of administering chemotherapy by these two routes is that tumor
cells throughout the body would be exposed to the chemotherapy. However, the disadvantage
is that sensitive tissues such as in the bone marrow and mucosa will also be equally exposed
to these chemotherapeutic drugs. So the main goal of I.V administration of chemotherapy is
to achieve a systematic chemotherapy concentration that is effective for the cancer treatment
of the cancer concerned [32]. When the chemotherapy is administered by the I.V. route, the
entire dose of the chemotherapy drug will be in the blood circulation and produce its effect on
the cancer cells. This will also lead to an increase in its adverse effect as compared to the oral
route whereby the drugs will be slowly absorbed and the concentration will increase gradually
thus not producing major side effects. But there will be no difference between the oral and the
I.V. route in the part concerned with neutropenia incidence, onset, or severity, since neutro‐
penia is related to chemotherapeutics intensity and effects but not with the route of adminis‐
tration [32, 33].
Jassem et al. (2003) focused on the effect of oral and I.V. administration of chemotherapeutic
drugs on neutropenia incidence. In their study, 56 patients were treated with vinorelbine and
cisplatin for their non-small cell lung cancer (NSCLC). On day 1 both drugs were given via
I.V. route, and this was followed by cisplatin I.V. and vinorelbine oral on days 8, 15, and 22.
The cycle was repeated every 28 days. The great and the predominant side effect observed was
neutropenia, that is, 73% of the patients had grade 3 (severe) and 4 (life threatening) neutro‐
penia and anemia had a lower percentage of incidences. Thus, Jassem and his colleagues’ study
demonstrated that the route of chemotherapy administration has no significant effect on their
pharmacological action, since both routes produced similar efficacy and safety as well as
similar side effects. However, the important point of their study was the new approach of I.V.
administration on day 1, and oral administration on days 8, 15, and 22 which is more suitable
and comfortable to the patients. However, the route of administration had no effect on the
chemotherapy toxicity since neutropenia and anemia were still the major side effects produced
by these chemotherapeutics drugs [34].
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9.2. Impact of chemotherapy cycles and schedule on neutropenia
It is preferred to administer on a continuous basis for maximal cancer cell killing and to
decrease the development of cancer cells resistance. However, chemotherapy toxicity results
in the destruction of normal cells, and thus should be stopped for sufficient intervals so as to
allow normal cells to recover. The duration of chemotherapy administration is known as
chemotherapy cycle. Neutropenia incidence is mainly and highly associated with the first cycle
of the chemotherapy more than the other or subsequent cycles. Indeed, the depletion of the
bone marrow will lead to decreased production of the neutrophils and neutropenia which
mainly occur with the first cycle of chemotherapy.
The association was determined by a study conducted in the United States of America by
Crawford et al. (2005) The study included more than 4,000 cancer patients age ranged from 18
to 97 years. More than 100 different chemotherapeutic regimens were reported and the most
frequently used chemotherapeutics were anthracyclines (35%), platinum compounds (33%)
and fluorouracil (20%). Neutropenia occurrence after the first cycle of the chemotherapy was
documented in 2,160 patients. Neutropenia with ANC nadir of < 1 × 109 cell/ L was observed
in 43% of the patients, while severe neutropenia (ANC nadir < 0.5 × 109 cell/ L) was seen in 24%
of the studied population. Fourteen percent of the patients had febrile neutropenia, while
severe febrile neutropenia was found in 9% [35].
Another study in the United States conducted by Wolf et al. (2005) on 2,222 cancer patients
showed that one-third of them were treated with fewer than four cycles of the chemotherapy
due to complications. The most important result obtained was that half of the cases of
neutropenia occurred during the first cycle of chemotherapy, especially among breast cancer
patients [36].
The relationship between chemotherapy and neutropenia was also reported by Schallier et
al. (2007). He conducted a study in Belgium on 48 non-small lung cancer patients treated
with three cycles of paclitaxel,  carboplatin, and gemcitabine. Schallier and his colleagues
aimed to detect the toxicity of these chemotherapies after each cycle. The results of their
study showed that the chemotherapy-induced neutropenia happened on days 8 and 15 of
the first cycle. During the second cycle, 34 out of 42 patients developed neutropenia on day
15. Neutropenia was also prominent on day 15 of the third cycle, during which 24 out of
42  patients  developed it.  Therefore,  the  study showed that  there  was  a  strong relation‐
ship  between  chemotherapy  cycle  and  neutropenia  incidence.  However,  there  was  no
significant  relationship  between  chemotherapy  cycle  and  neutropenia  severity,  which
remained the same across the three cycles [37].
Neutropenia severity mainly increases due to chemotherapeutic drugs schedules [38].
Chemotherapeutic drugs are usually administered in a manner that will enhance their main
benefits and reduce or prevent their toxic effects [32, 33, 39], but the duration of administration
is also controlled by the pharmacokinetic and pharmacodynamic characteristics of the drug
used, as some chemotherapeutic drugs can cause severe bone marrow suppression, such as
the alkylating agent cyclophosphamide. These drugs are usually administered by pulse
method, that is, for a short period (usually 1 day) followed by a long interval before the next
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dose is given. This will give time for both the bone marrow and neutrophils to recover [40].
When given on a longer administration schedule, drugs such as 5-flurouracil will lead to the
inhibition of RNA synthesis of the cancer cells, thus killing them. However, when given as a
single bolus dose they will lead to the inhibition of thymidylate synthesis, which will result in
severe side-effects. On the other hand, paclitaxel, when given for more than 1 day, will mainly
lead to severe toxicity and cause more destruction of the bone marrow. However, when given
for 1 day, paclitaxel will render the desired anticancer effect, with fewer effects on bone
marrow. The standard interval between each cycle, whether the cycle lasts 1 day or more,
ranges from 21 to 28 days [32, 33, 39].
10. Prevalence and incidence of neutropenia
Neutropenia generally occurs in one out of three patients treated with chemotherapy. Once
neutropenia happens, it may threaten the patient’s life, and chemotherapy schedule or dose
should be delayed in order to give the body a chance to produce new neutrophils [41, 42, 43,
44]. Although neutropenia is common during chemotherapy, severe neutropenia is not and
can cause serious morbidity and mortality due to resulting infections. Epidemiological studies
have shown a wide variation in neutropenia incidence according to geographic regions. The
average incidence of neutropenia in the United States is 56.4 per million people. There are no,
or very few studies that give an exact number of neutropenia prevalence [45].
11. Risk factors for neutropenia
11.1. Gender
The female gender is a risk factor for neutropenia and febrile neutropenia. The possible reason
for the higher number of females than males with neutropenia is that the incidence of cancer
in females is generally higher than that in males by a ratio of 1:1.3 [46]. Moreover, it has also
been reported that 49% of the solid cancer patients who developed neutropenia during
chemotherapy were diagnosed with breast cancer. Since breast cancer occurs mostly in
females, this could also explain the higher number of females with neutropenia [17, 47]. A
study by Wolf et al. (2005) in the United States looked at the risk factors associated with
neutropenia among 2,222 patients. The main results showed that there were significant
associations of neutropenia severity and gender (P= 0.001) and between complication and
gender (P= 0.004) [47]. An observational retrospective study was conducted by Bassam et al.
(2009) on solid cancer patients admitted to Penang Hospital in 2003 - 2006 who became
neutropenic during chemotherapy. The results show an insignificant association between
incidence and neutropenia severity with patients’ demographic data, leading to the conclusion
that the demographic data is not a risk factor for neutropenia incidence or severity. However,
the main reason for this insignificance was the small sample size [18].
A Close Look at Neutropenia among Cancer Patients — Risk Factor and Management 9
11.2. Age
Neutropenia is more common among the elderly (i.e., 50 years of age or older). Indeed these
individual are already less able to produce mature neutrophil cells [2, 8, 13, 17]. According to
the National Cancer Registry of Malaysia (2003), cancer incidence, especially breast cancer
incidence, is more predominant at the age of 50 years or more. Yip and Omar Hasan Kasule
(2005) reported that neutropenia occurred mostly in people aged 50 - 59 years and 75% of the
neutropenic patients in their study were diagnosed with breast cancer [48, 49]. In his study,
Crawford (2007) investigated 282 lymphoma cancer patients treated with cyclophosphamide,
doxorubicin, vincristine and prednisolone (CHOP), and said that the incidence of neutropenia
was predominant among individuals aged 65 years or more compared to younger than 65
years of age [50]. Moreover, in the United States, Voelker et al. (2004) carried out a retrospective
study from 1991 to 1999 on 7,238 patients with non-Hodgkin lymphoma (NHL). The main
objective was to find the major risk factors associated with initiation and duration of hospi‐
talization among neutropenic patients after chemotherapy. The median age was 75 years
(range: 66 to 100 years). About 22% of patients needed hospitalization and half were first
admitted within the first 42 days of treatment. The mean duration of hospitalization was 55.7
± 1.43 days and the median was 34 days. The risk factors found to be associated with hospital
admission were patients’ age, gender, chemotherapy type, history, and disease stage. The risk
of hospitalization due to neutropenia increased with age until the age of 80 years [51]. So the
study by Voelker et al. (2004) demonstrated a significant association between neutropenia and
patients’ age and gender. At these advanced ages, chemotherapy doses usually reduced and
the administration of G-CSF (Filgrastim) is increased [17, 36].
11.3. Ethnic group
The ethnic group has been suggested to have a significant effect on ANC and therefore there
is a relationship between these variables and neutropenia [13]. However, some specific types
of cancers are highly associated with specific races. According to Kaur et al. (2007), breast cancer
incidence in Penang mostly occurs among the Chinese (62.5%), followed by the Malays (26.7%),
and the Indians (10.2%), and breast cancer is most highly associated with neutropenia (Wolf
et al., 2005), which could indicate that the ethnic group does play a role in the incidence of
neutropenia [32, 52].
Moreover, in the United States, another study by Hershman et al. (2003) also showed that there
is an association between ethnicity and neutropenia (WBC level) in breast cancer survivors.
Their study was performed on African American and White American women with breast
cancer (stage I and II) treated with chemotherapy. It showed that the WBC level in African
American women was significantly lower than that of White American women. There was
also a significant difference between the period of chemotherapy treatment of African
American (19 women) versus White American women due to neutropenia. The explanation
for the difference in period of treatment was said to be due to lower ANC. Besides that,
neutropenia occurrence led to a delay in chemotherapy administration. Therefore, their study
demonstrated a significant association between neutropenia occurrence and ethnicity [53].
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12. Neutropenia and cancer type
12.1. Solid cancer
Neutropenia has been shown to be associated with solid tumors especially breast cancer, as
about 25% of breast cancer patients develop neutropenia. Lyman and Wilmot (2006) and Wolf
et al. (2005) found that among patients with solid cancer, breast cancer patients had the highest
risk for developing severe neutropenia and febrile neutropenia during the first cycle of
chemotherapy. Due to the neutropenia, 40% of the breast cancer patients had the chemotherapy
delayed and about 25% had their chemotherapy treatment doses reduced. The possibility of
breast cancer patients to develop neutropenia at point during chemotherapy was 78% [17, 32].
Patients with solid tumors usually have normal neutrophil cell function as compared to
patients with hematological malignancies, whose neutrophil function is completely abnormal
and thus would suffer from neutropenia. Patients with solid tumors are also not immuno‐
compromised as are those with hematological malignancies, and many centers now consider
solid tumor patients to have a low risk of neutropenia [54, 55]. A significant association was
also found between cancer type and neutropenia duration, but not between cancer type and
neutropenia severity [56]. The study by AL-Ahwal (2005) also showed that the association
between neutropenia severity and solid cancer was not significant, but that co-morbidity of
chemotherapy with solid cancer was significant. Among breast cancer with neutropenia, more
than 75% of cases seemed to be associated with the type of chemotherapy employed, which
was CMF [17]. In a retrospective study on 117 solid cancer patients with neutropenia conducted
by Bassam and colleagues in Penang, the type of solid cancer played an insignificant role in
the incidence and/or neutropenia severity. The main explanation for this result was that
patients with a solid tumor are different from those with hematological malignancy, in the
sense that solid tumor patients usually have normal neutrophil cell function. While, in case of
hematological malignant patients where by their neutrophil cells function is completely
abnormal and thus they suffer from neutropenia. In contrast, neutropenia occurrence among
solid cancer patients usually starts after chemotherapy, and severe neutropenia may last for 7
- 10 days. Thus the main cause of neutropenia is not the presence of cancer itself, but the
chemotherapeutic agents or drugs used. For this reason solid tumor patients who developed
neutropenia are considered to be at low risk for neutropenia [26].
12.2. Hematological cancer
Patients with hematological malignancies are necessarily immunocompromised, either as a
result of the malignancy or due to the therapeutic interventions used to manage it. Some
hematological malignancies are associated with specific immune defects that predispose to
infections with particular pathogens. For example, patients with acute leukemia have an
increased risk of severe gram-negative bacterial infections as a result of quantitative or
functional neutropenia. Patients with chronic lymphocytic leukemia and multiple myeloma
are susceptible to invasive bacterial infections from staphylococci, streptococci, and especially
pneumococcus. Patients with lymphoma have abnormalities of the cellular immune system
that result in an increased risk of viral (e.g., herpes simplex) and fungal infections (e.g.,
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cryptococcus). Moreover, therapeutic interventions such as corticosteroids, chemotherapy,
stem cell transplant, and radiation also produce deficiencies in the host immune defense [57].
Neutropenia due to chemotherapy is the most common risk factor for severe bacterial
infections in hematological malignancies. Impaired T-cell function in patients undergoing
allogenic stem cell transplant is associated with an increased susceptibility to invasive viral
infections. It can also induce alterations in host colonization, such as disruption of natural skin
and mucosal barriers, and can interfere with nutrition, which can cause an increase in the risk
of infection. Therefore, the degree of neutropenia either as a consequence of the disease or the
therapy, is directly related to the incidence of serious bacterial and fungal infection in patients
with hematological malignancies. There is a significant increase in the incidence of serious
infection once ANC falls below 500 cells/μl. Patients with ANC below 100 cells/μl are at the
highest risk of infection. The duration of neutropenia also contributes significantly to the risk
of serious infections. Qualitative defects in neutrophil function have been described in
hematological malignancies. These include defects in chemotaxis, phagocytosis, bactericidal
capacity, and the absence of respiratory burst that accompanies phagocytosis. Additionally,
chemotherapeutic regimens used in association with corticosteroids can decrease phagocytosis
and neutrophil migration [57].
13. Management of neutropenia
13.1. Granulocyte colony stimulating factors
Granulocyte colony stimulating factors are glycoproteins that regulate the proliferation,
differentiation, functional activity and survival of myeloid cells, which help in reducing the
duration and neutropenia severity as a result of chemotherapy [8]. Moreover, G-CSF treatment
can significantly reduce hospitalization period and frequency neutropenic patients, and
reduce the amount of antibiotics used [8]. G-CSF such as Filgrastim (Neupogen®) can be used
to prevent, reduce, or palliate neutropenia in patients treated with chemotherapy. Filgrastim
has also been shown to decrease the incidence of febrile neutropenia and to improve survival.
Moreover, G-CSF have also been shown to decrease neutropenia severity. Both G-CSF and
granulocyte-macrophage colony stimulation factors (GM-CSF) (Sargramostim®) have been
approved by the United States Food and Drug Administration for the treatment of neutropenia
[2, 8]. But G-CSF use is preferred as it is more effective and has a lower side-effect [8]. A study
on the efficacy of the G-CSF in reducing neutropenia among solid tumor and lymphoma
patients receiving chemotherapy was carried out by Lyman et al. (2002). In their study, G-CSF
was administered before the occurrence of fever and neutropenia. There were 1144 patients
with eight trials, five with filgrastim and three with lenograstim. The results showed that G-
CSF reduced the risk of febrile neutropenia (odd ratio [OR] 0.38, 95% [CI]: 0.29 - 0.49). However,
the reduction of infection-related mortality was insignificant (OR= 0.6, 95% CI 0.3 - 1.22). There
were no differences in treatment effect by cancer type. The study demonstrated that there was
a significant association between the G-CSF and the reduction of neutropenia risk [58].
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Juan et al. (2001) carried out a prospective study in Spain on 44 solid cancer patients between
1997 and 1999. The aim of the study was to compare the effectiveness of different doses of G-
CSF (lenograstim) on neutropenia. The doses used were 263 micrograms/day (full dose) and
131.5 micro grams/ day (half dose). Of the 44 patients, 39 (88.6%) developed neutropenia after
chemotherapy. A total of 120 courses of chemotherapy were given to the patients, full doses
were given in 61 courses and half a dose of lenograstim was given in 59 courses. The results
of the study showed that severe neutropenia was more common among patients who received
low doses of lenograstim (20%) as compared to the full dose of lenograstim (12%), but the
difference was not significant (P= 0.1). The frequency of fever and hospital admission was not
affected. The mean ANC with full doses of lenograstim was higher than with half doses, but
was again not significant (P= 0.324). Juan concluded that both doses of lenograstim had a
similar efficacy in reducing neutropenia severity [59].
All the above studies showed that G-CSF should be the primary treatment for severe and febrile
neutropenia. This is also in accordance with Malaysian treatment guidelines for febrile
neutropenia (i.e., severe neutropenia) treatment [60], which indicate that G-CSF should be
considered in patients with febrile neutropenia with high risk features. In the case of severe
febrile neutropenia (ANC less than 0.1× 109 cells/L), or in the presence of signs and symptoms
of infection, antibiotics, must, be used with G-CSF [8].
13.2. Antimicrobial therapy
Empirical antibiotic therapy is required in neutropenia especially, when it is combined with
gram-negative bacterial infection, as this combination is associated with high mortality. This
point is supported by Schimpff (2001), who mentioned that if fever is not taken seriously and
the neutropenic patient is suffering from a bacterial infection, 40% will die within the first 48
hours [61]. This is because there are no reliable methods to determine whether neutropenic
fever is due to bacterial infection or not. Thus, antimicrobial therapy must be started either as
mono antibiotic therapy or a combination antibiotic therapy. This reduces the mortality of
gram-negative infection by 10% [62]. Any empirical antibiotic used must have a wide range
of activity, enough to cover the majority of potential pathogens. There are three different
universal strategies for using antibiotics in the treatment of febrile neutropenia: (i) a combi‐
nation of either beta-lactam with aminoglycoside, (ii) monotherapy with wide range beta-
lactam, and (iii) both of the above strategies combined [62]. Most neutropenic patients are
treated with a beta-lactam antibiotic such as ceftazidime which is widely used as a single
empirical antibiotic for neutropenic fever because its effectiveness is very similar to combina‐
tion therapy. Other beta-lactam antibiotics such as imipenem, ticarcillin and cefepime may
also be used as monotherapy or in combination with metronidazole or aminoglycoside
(amikacin and gentamicin) to overcome bacterial infection, especially gram-negative bacteria.
Penicillin derivatives such as piperacillin and tazobactam can also be used alone or in combi‐
nation with beta-lactam derivatives such as imipenem to overcome anaerobe bacterial
infection. The new generations of beta-lactam antibiotics have shown wide protection against
both gram-positive and gram-negative bacteria such as cefepime [63]. Therefore, ceftazidime
or imipenem could be used as first-line treatment while awaiting the results of a culture and
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sensitivity test [2]. This is also in accordance with Malaysian antibiotic guidelines for febrile
neutropenia (i.e., severe neutropenia) treatment [61, 64]. According to the United States Food
and Drug Administration, there are many types of antibiotics that could be used to treat
neutropenic patients. However, there are only a limited number of antibiotics that are effective
for the treatment of febrile neutropenia (i.e., severe neutropenia). Ceftazidime is considered
one of the most effective antibiotics and has been approved for the treatment of febrile
neutropenic patients at different ages [65].
Combination therapy is also used when there is a need, when there is resistant bacteria in
neutropenic patients, or even because of neutropenia severity [62]. In the United States,
cephalosporin (mainly ceftazidime) is frequently used as an initial single empirical antibiotic
for the treatment of febrile neutropenia. The combinations of cephalosporin plus vancomycin,
third generation cephalosporin plus penicillin, or carbapenem plus aminoglycoside are also
used. These combinations have been recommended for patients who were suspected to be or
are suffering from resistance gram-negative bacterial infection [8]. The same result was found
by De Pauw et al. (1994) who conducted a study on 692 cancer patients suffering from febrile
neutropenia. In their study the patients either received 2g ceftazidime every 8 hours, or 14 -
16 g/ day of piperacillin, in 4 - 6 divided doses plus tobramycin 1.7 - 2 mg/kg of body weight
every 8 hours. Their results showed that mortality due to infections was 6% with ceftazidime
and 8% with piperacillin plus tobramycin. Adverse effects of ceftazidime occurred in 8% of
patients, compared to 20% who received combination antibiotics. The main conclusion made
by De Pauw and his colleagues was that ceftazidime as monotherapy was as effective as
piperacillin plus tobramycin, and that ceftazidime was much safer in the treatment of febrile/
severe neutropenic patients [65].
Another  study  in  Japan  by  Yano  and  Nakano  (1996)  looked  at  the  use  of  antibiotic
monotherapy in 43 patients suffering from hematological toxicity. Eighteen of these patients
suffered  from severe  neutropenia  (ANC <  500  cells/μl).  The  patients  were  treated  with
cefpirome or a combination of two beta-lactam antibiotics. The results showed that 89.5%
of patients on cefpirome had a better quality of life, a decreased number of infusions, and
a  decrease  in  the  frequency  of  antibiotic  administration.  Cefpirome  use  also  led  to  a
reduction in night urination, a low cost/benefit ratio and a reduction in nursing responsibil‐
ities. Due to this high efficacy rate, cefpirome monotherapy is therefore considered a first
line treatment for patients with hematological diseases,  and especially those with severe
neutropenia, suffering from infection [66].
The effectiveness of antibiotic monotherapy was again supported by Tamura et al. (2001), who
compared the effectiveness of antibiotic monotherapy and combination antibiotics in neutro‐
penic patients. One hundred sixty five patients were enrolled in the study, with an average
age of 52 years. Severe febrile neutropenia was found in the 60% of patients (ANC < 100 cells/
μl). The patients were divided into two groups. One group was treated with antibiotic
monotherapy (either cefepime or carbapenem) and the other was treated with a combination
of cefepime and aminoglycoside. Two- thirds of the patients from both groups showed that
infection was overcome with antibiotic treatment. The conclusion was that the use of antibiotic
monotherapy is as good and effective as combination antibiotics in the treatment of febrile
Cancer Treatment14
neutropenic patients. As mentioned the use of antibiotic monotherapy (ceftazidime or
cefepime) was also emphasized by the Malaysian Ministry of Health. Indeed, while the uses
of dual therapy may be preferred in cases with severe neutropenia, a prolonged duration
should be expected, as should complications, such as sepsis, hypotension, mucositis and
recurrent episodes [67].
13.3. Antibiotics schedule
According to the guidelines from the Infectious Society of America, neutropenic patients who
remained febrile but showed recovery in ANC on the third day of antibiotic therapy can either
continue with antibiotic treatment for 7 days, or antibiotic treatment can be stopped on the
fourth or fifth day. For those febrile neutropenic patients with no recovery in ANC, antibiotics
should be continued, and can be discontinued after 2 weeks if examinations and cultures show
no bacterial growth [68]. Hughes et al. (2002) reported that antibiotic schedule for neutropenic
patients is mainly determined and controlled by ANC (i.e., neutropenia severity). Antibiotic
treatment can be stopped after 3 days if there is no infection. Indeed, continuing antibiotic
treatment until the neutropenia is resolved is not preferred as it could lead to increased drug
toxicity and bacterial resistance. Thus, Hughes and his colleagues suggested a preferred
treatment of antibiotics for 5 - 7 days; antibiotics could be stopped before 5 days if there is
evidence of hematological recovery [69].
In Canada, a study by Tomiak et al. (1994) looked at the antibiotic schedule used in 134 febrile
neutropenic patients and its effect on duration of hospital stay. The study showed that
antibiotics can be stopped within 4 - 5 days especially for patients whose culture shows no
bacterial infection. The association between neutropenia and antibiotic reduction was signif‐
icant (P<0.001) [70].
14. Types of route antibiotics administration according to risk of infection
14.1. Low risk neutropenic patients (Oral therapy)
A recent review has reported that inpatient oral antibacterial therapy can be safely replaced
with conventional intravenous treatment among low-risk patients with febrile neutropenia,
namely, those who are clinically stable, who do not suffer from acute leukemia, pneumonia,
severe soft tissue infection, and who do not have any evidence of organ failure. Among these
patients single-agent quinolone was not inferior to combinations of quinolone with amoxicillin
plus clavulanic acid, but the latter is preferred when laboratory test show gram-positive
infections. Moreover, oral quinolone therapy should not be administered to patients who have
already received quinolone as a prophylaxis [71].
14.2. High risk neutropenic patients
The majority of the treatment guidelines indicate that high-risk neutropenic patients need to
be treated with using parenteral broad spectrum antibiotic therapy, that is using standard,
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hospital-based guidelines. For a long time, the most common approach was the selection and
use of combination antimicrobial therapy (beta-lactam plus aminoglycoside antibiotics) [72].
14.3. Duration of therapy
According to the guidelines from the Infectious Society of America, neutropenic patients who
remain febrile but show recovery in neutrophil cell count on the third day of antibiotic therapy
could either continue with antibiotics treatment for 7 days or antibiotic treatments can be
stopped on the fourth or fifth day.
For those neutropenic febrile patients with no recovery in the ANC it is preferred to continue
antibiotics which could only be discontinued after 2 weeks when the examination and cultures
show no bacterial growth [69].
14.4. Antifungal drugs
Fungal treatment is one of the most important steps for neutropenic patients. Even one positive
blood culture for candida should be considered significant. Patients with disseminated
candidiasis should be treated with fluconazole, which is as effective as amphotericin B and
less toxic. If the patient is not stable and has already received fluconazole, amphotericin B is
recommended. The treatment should continue until all signs of infections are resolved for a
minimum of 2 weeks. Patients with invasive fungal infection are at risk of recurrent infection
due to chemotherapy-induced neutropenia [73].
14.5. Antiviral drugs
The main characteristic of viruses is their simple structure, which helps them multiply. Viruses
use the biochemical mechanisms of the host cell to produce new protein and genes. This makes
the virus and the host cell identical and makes it difficult for the antiviral drug to distinguish
the viral cell from the host cell. In the last couple of years, further information on the mechanism
of viral multiplication has helped in the development of antiviral drugs such as acyclovir,
which is effective against some herpes viruses. On the other hand, the increase in the use of
immunosuppressive drugs had led to an increase in both bacterial and viral infections [74].
15. Conclusion
Neutropenia is a critical condition occurring among patients undergoing chemotherapy. It is
strongly associated with a number of negative experiences that have an adverse effect on
patients’ quality of life. Neutropenia can lead to and is associated with critical infection of
bacterial, fungal, or viral origin which may cause death if not treated. But survival in neutro‐
penic patients can improve overtime with the uses of empirical antibiotic treatment (mono‐
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